Mô hình điều trị và phân tích so sánh các chế độ không mạnh đối với bệnh nhân cao tuổi bị bệnh bạch cầu myeloid cấp tính - một trải nghiệm thực tế từ Ấn Độ

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30 Klepin HD, Balducci L (2009) Acute myelogenous leukemia in older adults. Oncologist 14(3):222–232 Alibhai SMH, Leach M, Minden MD, Brandwein J (2009) Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer 115(13):2903–2911 Leith CP, Kopecky KJ, Chen IM, McConnell T, Slovak ML, Head DR, et al AML in the Elderly: a Biologically Distinct Disease in which MDR1 Expression and Unfavorable Cytogenetics Contribute to Poor Clinical Response. Studies of the Southwest Oncology Group. In: Acute Leukemias VII. Berlin, Heidelberg: Springer Berlin Heidelberg; 1998. pp. 413–21. (Haematology and Blood Transfusion / Hämatologie und Bluttransfusion; vol. 39) Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK et al (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109(6):1114–1124 Fathi AT, Abdel-Wahab O (2012) Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol 2012(12):469592–469512 Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Finelli C, Giagounidis A et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223–232 Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670–2677 Smith BD, Beach CL, Mahmoud D, Weber L, Henk HJ (2014) Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis. Exp Hematol Oncol 3(1):10 Ozbalak M, Cetiner M, Bekoz H, Atesoglu EB, Ar C, Salihoglu A et al (2012) Azacitidine has limited activity in “real life” patients with MDS and AML: a single centre experience. Hematol Oncol 30(2):76–81 Radujkovic A, Dietrich S, Bochtler T, Krämer A, Schöning T, Ho AD et al (2014) Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts – a retrospective single-center experience. Eur J Haematol 93(2):112–117 Jacob LA, Aparna S, Lakshmaiah KC, Lokanatha D, Babu G, Babu S et al (2015) Decitabine compared with low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia: a pilot study of safety, efficacy, and cost-effectiveness. Adv Hematol 2015(12):1–6 Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA et al (2015) Acute myeloid leukaemia: challenges and real world data from India. Br J Haematol 170(1):110–117 Mukhopadhyay S, Chitalkar P, Gupta P, Roy U, Mukhopadhyay A (2016) Oral chemotherapeutic agents in elderly acute myeloid leukemia (AML) patients, a study from a developing country. Journal of Clinical Oncology. American Society of Clinical Oncology Kapoor A, Beniwal SK, Kalwar A, Singhal MK, Nirban RK, Kumar HS (2016) Metronomic therapy with oral 6-mercaptopurine in elderly acute myeloid leukemia: a prospective pilot study. South Asian J Cancer 5(2):70–72 Tandon N, Banavali S, Menon H, Gujral S, Kadam PA, Bakshi A (2013) Is there a role for metronomic induction (and maintenance) therapy in elderly patients with acute myeloid leukemia? A literature review. Indian J Cancer 50(2):154–158 Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood. American Society of Hematology 116(3):blood–2009–11–254441–365 Gavillet M, Noetzli J, Blum S, Duchosal MA, Spertini O, Lambert J-F (2012) Transfusion independence and survival in patients with acute myeloid leukemia treated with 5azacytidine. Haematologica 97(12):1929–1931 Al-Ali HK, Jaekel N, Junghanss C, Maschmeyer G, Krahl R, Cross M et al (2011) Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 53(1):110–117 Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C (2015) Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. Ann Hematol 94(7):1127–1138 Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille M-H et al (2016) An evaluation of treatment patterns and outcomes in elderly patients newly diagnosed with acute myeloid leukemia: a retrospective analysis of electronic medical records from US community oncology practices. Clin Lymphoma Myeloma Leuk 16(11):625–636.e3 Oran B, Weisdorf DJ (2012) Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 97(12):1916–1924 Juliusson G, Lazarevic V, Hörstedt A-S, Hagberg O, Höglund M, Swedish Acute Leukemia Registry Group (2012) Acute myeloid leukemia in the real world: why populationbased registries are needed. Blood 119(17):3890–3899 Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447 Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126(3):291–299 Serrano J, de la Fuente A, Bergua J, Falantes J, Eusebio M-C, Antonio LJ et al (2011) 5Azacytidine versus intensive chemotherapy or BSC in elderly (>60 years) acute myeloid leukemia patients. A retrospective analysis. Blood 118(21):2612–2612 Thépot S, Itzykson R, Seegers V, Récher C, Raffoux E, Quesnel B et al (2014) Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol 89(4):410–416 Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J et al (2015) Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. Leuk Res 39(3):296–306 Schuh AC, Döhner H, Seymour JF, Turlure P, Junghanss C, MacWhannell A et al (2017) Stable disease with hematologic improvement is clinically meaningful for older patients with Acute Myeloid Leukemia (AML) treated with azacitidine. Leuk Res 55:S68–S69 Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström-Lindberg E, Santini V et al (2010) Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 76(3):218–227